Description: Aequus Pharmaceuticals Inc. is a Vancouver-based specialty pharmaceutical company focused on developing, advancing and promoting differentiated products in Canada. Aequus development pipeline focuses on enhancing delivery methods for approved drugs that are limited by non-compliance, high frequency dosing, first-pass metabolism side-effects, painful injections, or where the therapeutic profile can be improved by making an alternative delivery system available. Aequus is developing several products in neurology and psychiatry with a goal of addressing the need for improved medication adherence through enhanced delivery systems. Aequus intends to commercialize its internal programs within Canada and to establish strategic partnerships to accelerate and maximize the potential of its product candidates worldwide.
Home Page: www.aequuspharma.ca
200 Granville Street
Vancouver,
BC
V6C 1S4
Canada
Phone:
604 336 7906
Officers
| Name | Title |
|---|---|
| Mr. Douglas Glen Janzen | Chairman, CEO & Pres |
| Ms. Ann Fehr CGA, CPA | CFO & Corp. Sec. |
| Mr. Stuart Fowler | Strategic Commercial Advisor & Independent Director |
| Mr. Grant Larsen | Chief Commercial Officer |
Exchange: OTCQB
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 32.7765 |
| Price-to-Sales TTM: | 1.4364 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 14 |